Publication | Open Access

Computational investigation into Nirematrelvir/Ritonavir synergetic efficiency compared with some approved antiviral drugs targeting main protease (Mpro) SARS-CoV-2 Omicron variant

MedicineImmunologyNirematrelvir/ritonavir Synergetic EfficiencyAntiviral ResponseVirologyAntiviral Drug DevelopmentAntiviral TherapyAntiviral DrugPharmacologyAntiviral CompoundMain ProteaseApproved Antiviral DrugsDrug DiscoveryCovid-19